Press Release: Announcing Issue Four of Rx Data News: Vital Pharma Business and Technology Intelligence Found Nowhere Else

Contact: Peter Grant
Phone: (425) 233-5075

BROOKLYN, NY USA -- HEALTHCARE UPDATE NEWS SERVICE™ -- APRIL 4, 2019: Announcing the release of the 4th Edition of Rx Data News, a publication dedicated to exploring the impact of data science, analytics, machine learning and artificial intelligence on the biopharmaceutical Industry.

SPECIAL SAVINGS: Visit our subscription page today and enter to following PROMO CODES:

  • RXDATA20 - 20% Off an Individual Subscription ($250 value)
  • RXDATA30 - 30% Off a Group Subscription - 10 Licenses ($1500 value)
  • RXDATA40 - 40% Off an Enterprise Subscription - up to 50 Licenses ($3800 value)


  • Exclusive Interview: Dr. James Cai, Head of Data Science, Roche Translational Clinical Research Center
  • Data Integrity: Regulators and Pharma Industry Seek New Solutions to Data Manipulation and Falsification
  • Monthly Deep Focus: What Impact has Data Science and the Technologies Associated with it had on Pharmaceutical Research & Development?
  • Deep Focus Response: Dr. Mats Sundgren, Director, Health Informatics, AstraZeneca
  • Industry Reports and Surveys Emphasize Importance of Data Standardization, Quality and Access
  • Deep Focus Response: Dr. Dan Riskin, Founder and CEO, Verantos
  • Accenture, Merk and Amazon Web Services (AWS) Collaborate on Cloud-Based Informatics Research Platform: In-Depth Interview
  • Monthly Rx Data News-in-Brief


Dr. James Cai
Head of Data Science, Roche Translational Clinical Research Center, New York, NY

Dr. Mats Sundgren
Director, Health Informatics, AstraZeneca, Stockholm, Sweden

Dr. Dan Riskin
Founder and CEO, Verantos, Palo Alto, CA

Joe Donahue
Managing Director, Life Sciences R&D, Accenture, Philadelphia, PA

Hal Stern
Executive Director of Applied Technology, Merck & Company, New York, NY

Visit to download a free sample issue and SUBSCRIBE today. Every issue contains originally reported articles, exclusive interviews and thought leader commentary.